Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 11:20 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1585–1608 of 3,096 matching trials from the live ClinicalTrials.gov search.
Filters: Sponsor: M.D. Anderson Cancer Center Clear all
Completed Phase 3 Interventional

Combination Chemotherapy in Treating Patients With Lymphoma

NCT00002835
View directory record Official record
Conditions
Lymphoma
Interventions
Bleomycin Sulfate (BLM), Filgrastim (G-CSF), Recombinant Interferon Alfa, Carmustine, Cisplatin (CDDP), Cyclophosphamide, Cytarabine (ARA-C), Etoposide (VP-16), Idarubicin, Ifosfamide, Leucovorin Calcium, Melphalan, Methotrexate, Methylprednisolone, mitoxantrone hydrochloride (DHAD), Vincristine Sulfate, Peripheral Blood Stem Cell Transplantation, Radiation Therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
15 Years to 59 Years
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2004
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 15, 2018 · Synced Oct 19, 2026, 11:20 PM EDT
Terminated Phase 1 Interventional

Sorafenib and Thoracic Radiation for Patients With Non-Small Cell Lung Cancer

NCT00543335
View directory record Official record
Conditions
Lung Cancer
Interventions
Sorafenib, Radiation Therapy
Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 15, 2018 · Synced Oct 19, 2026, 11:20 PM EDT
Completed Not applicable Interventional

Standard and Delayed FDG PET/CT After Chemoradiation Therapy in Assessing Patients With Metastatic Head and Neck Squamous Cell Cancer

NCT03575949
View directory record Official record
Conditions
Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Malignant Neoplasm in the Spine
Interventions
Computed Tomography, Fludeoxyglucose F-18, Positron Emission Tomography
Procedure · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 14, 2024 · Synced Oct 19, 2026, 11:20 PM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Patient and Caregiver Attitudes and Beliefs Regarding Prescription of Intranasal Naloxone Spray for Opioid Overdose

NCT04129138
View directory record Official record
Conditions
Caregiver, Patient
Interventions
Survey Administration
Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
182 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 19, 2026, 11:20 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Oxaliplatin, Fludarabine, Cytarabine, and Rituximab in Patients With Richter's Transformation and Leukemias

NCT00472849
View directory record Official record
Conditions
Richter's Transformation, Leukemia
Interventions
Oxaliplatin, Fludarabine, Cytarabine, Rituximab, Pegfilgrastim
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 26, 2013 · Synced Oct 19, 2026, 11:20 PM EDT
Completed Phase 2 Interventional

A-dmDT390-bisFv(UCHT1) Immunotoxin Therapy for Patients With Cutaneous T-Cell Lymphoma (CTCL)

NCT00611208
View directory record Official record
Conditions
T-cell Lymphomas, T-cell Leukemia, Sezary Syndrome, Mycosis Fungoides, Cutaneous T-cell Lymphoma (CTCL)
Interventions
A-dmDT390-bisFv(UCHT1)
Biological
Lead sponsor
Virogen Biotechnology Inc.
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
5
States / cities
New Haven, Connecticut • Louisville, Kentucky • Dallas, Texas + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 29, 2016 · Synced Oct 19, 2026, 11:20 PM EDT
Completed Phase 1 Interventional

Rocking Motion: Physiologic Effect on the Surgical Stress Response

NCT01200316
View directory record Official record
Conditions
Gastrointestinal Cancer
Interventions
Standard of Care, Rocking Chair Motion, Questionnaire
Procedure · Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 30, 2017 · Synced Oct 19, 2026, 11:20 PM EDT
Completed No phase listed Observational

Prospective Validation Trial of Circulating Tumor Cells (CTCs) in Women With Metastatic Breast Cancer

NCT00493350
View directory record Official record
Conditions
Breast Cancer
Interventions
Blood Sample
Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Female only
Enrollment
660 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 31, 2012 · Synced Oct 19, 2026, 11:20 PM EDT
Recruiting Not applicable Interventional

STRICT - Surveillance With TRoponin During Immune Checkpoint Therapy

NCT06337097
View directory record Official record
Conditions
Immune Checkpoint Therapy
Interventions
Troponin surveillance, Standard of care
Diagnostic Test · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
980 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Oct 19, 2026, 11:20 PM EDT
Active, not recruiting Early Phase 1 Interventional

Nivolumab With or Without Bevacizumab or Ipilimumab Before Surgery in Treating Patients With Metastatic Kidney Cancer That Can Be Removed by Surgery

NCT02210117
View directory record Official record
Conditions
Clear Cell Renal Cell Carcinoma, Metastatic Kidney Carcinoma, Stage IV Renal Cell Cancer AJCC v7
Interventions
Bevacizumab, Biopsy, Ipilimumab, Laboratory Biomarker Analysis, Metastasectomy, Nivolumab, Therapeutic Conventional Surgery
Biological · Procedure · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Oct 19, 2026, 11:20 PM EDT
Recruiting Phase 2 Interventional

Neoadjuvant Immune Checkpoint Blockade + a Prebiotic Food-enriched Dietary Intervention to Optimize Immune Response in Melanoma: NEO-PreFED

NCT06548789
View directory record Official record
Conditions
Melanoma
Interventions
Prebiotic Xnack Packouts
Dietary Supplement
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 19, 2026, 11:20 PM EDT
Recruiting Not applicable Interventional

Feasibility and Clinical Utility of Cell-free DNA (cfDNA) in Identifying Actionable Alterations and Minimal Residual Disease for Lymphoma Patients Across Community Centers in Texas

NCT05676450
View directory record Official record
Conditions
Lymphoma
Interventions
cell-free DNA
Diagnostic Test
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
517 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
2
States / cities
Houston, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated May 20, 2026 · Synced Oct 19, 2026, 11:20 PM EDT
Terminated Phase 1 Interventional

Study Assessing the Feasibility, Safety and Efficacy of Genetically Engineered Glucocorticoid Receptor Knock Out Virus Specific CTL Lines for Viral Infections in Immunosuppressed Cancer Patients

NCT05101213
View directory record Official record
Conditions
Adenovirus Infection, BK Virus Infection, Cytomegaloviral Infection, Hematopoietic and Lymphoid Cell Neoplasm, JC Virus Infection, Malignant Solid Neoplasm, Symptomatic COVID-19 Infection Laboratory-Confirmed
Interventions
Virus-specific Cytotoxic T-lymphocytes
Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 19, 2026, 11:20 PM EDT
Completed Phase 2 Interventional Results available

Study of Allogeneic Umbilical Cord Blood Infusion for Adults With Ischemic Stroke

NCT03004976
View directory record Official record
Conditions
Stroke, Stroke, Acute, Brain Injury, Acute
Interventions
Umbilical Cord Blood, Placebo
Biological · Other
Lead sponsor
Joanne Kurtzberg, MD
Other
Eligibility
18 Years to 90 Years
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
6
States / cities
Aurora, Colorado • Gainesville, Florida • Atlanta, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 6, 2022 · Synced Oct 19, 2026, 11:20 PM EDT
Completed Not applicable Interventional Results available

Smartphone-Delivered Attentional Bias Modification Training in Helping Patients Quit Smoking

NCT02224391
View directory record Official record
Conditions
Current Every Day Smoker
Interventions
Computer-Assisted Smoking Cessation Intervention, Laboratory Biomarker Analysis, Nicotine Patch, Questionnaire Administration, Sham Intervention
Behavioral · Other · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 65 Years
Enrollment
311 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 7, 2023 · Synced Oct 19, 2026, 11:20 PM EDT
Completed Phase 2 Interventional Results available

Rituximab and Combination Chemotherapy in Treating Older Patients With Diffuse Large B-Cell Lymphoma

NCT00101010
View directory record Official record
Conditions
Lymphoma
Interventions
Filgrastim, Pegfilgrastim, Rituximab, Cyclophosphamide, Pegylated liposomal doxorubicin hydrochloride, Prednisone, Vincristine Sulfate
Biological · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
61 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2014
U.S. locations
7
States / cities
Fort Smith, Arkansas • Grand Rapids, Michigan • Kalamazoo, Michigan + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2020 · Synced Oct 19, 2026, 11:20 PM EDT
Active, not recruiting Not applicable Interventional

Accelerated Recovery After MIS Hepatectomy (ARAMIS Hep) to Support Early Discharge for Patients Undergoing Minimally Invasive Liver Resection

NCT05879159
View directory record Official record
Conditions
Liver
Interventions
Questionnaires
Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 19, 2026, 11:20 PM EDT
Completed Phase 1 Interventional

CD19-specific T-cell for Chronic Lymphocytic Leukemia (CLL)

NCT01653717
View directory record Official record
Conditions
Advanced Cancers, Leukemia
Interventions
Leukapheresis, Fludarabine, Cyclophosphamide, T-cell Infusion
Procedure · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 17, 2017 · Synced Oct 19, 2026, 11:20 PM EDT
Withdrawn Phase 1 Interventional

ALT-801-activated Natural Killer Cells After FLAG Induction for Acute Myeloid Leukemia

NCT01478074
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
G-CSF, Cytarabine, Fludarabine, Donor Natural Killer (NK) cells, ALT-801
Drug · Biological
Lead sponsor
Altor BioScience
Industry
Eligibility
2 Years to 59 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 3, 2014 · Synced Oct 19, 2026, 11:20 PM EDT
Not listed Phase 1 Interventional

Autologous CD8+ SLC45A2-Specific T Lymphocytes With Cyclophosphamide, Aldesleukin, and Ipilimumab in Treating Patients With Metastatic Uveal Melanoma

NCT03068624
View directory record Official record
Conditions
Metastatic Malignant Neoplasm in the Liver, Metastatic Uveal Melanoma
Interventions
Aldesleukin, Autologous CD8+ SLC45A2-specific T Lymphocytes, Cyclophosphamide, Ipilimumab
Biological · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 25, 2024 · Synced Oct 19, 2026, 11:20 PM EDT
Not yet recruiting Not applicable Interventional

iCCARE Project #4: Grounded Theory Study of the Social Determinants of Migrant Health Factors Impacting Prostate Cancer Care and Survivorship Among Sub-Saharan African and Caribbean Immigrant Men Diagnosed With Prostate Cancer

NCT07105020
View directory record Official record
Conditions
Prostate Cancer
Interventions
Interviews
Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 19, 2026, 11:20 PM EDT
Completed Not applicable Interventional

Selective Image Guided Resection of Axillary Lymph Nodes

NCT01880645
View directory record Official record
Conditions
Breast Cancer
Interventions
Fine Needle Aspiration (FNA), Ultrasound, Breast Surgery + Lymph Node Removal
Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 18, 2015 · Synced Oct 19, 2026, 11:20 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

MEK Inhibitor 162 Relapsed and/or Refractory Acute Myeloid Leukemia (AML) and Poor Prognosis, Not Suitable for or Unwilling to Receive Standard Therapy

NCT02089230
View directory record Official record
Conditions
Leukemia
Interventions
MEK 162
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 20, 2021 · Synced Oct 19, 2026, 11:20 PM EDT
Recruiting Phase 1Phase 2 Interventional

Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome

NCT03661307
View directory record Official record
Conditions
Acute Myeloid Leukemia, Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Recurrent Myelodysplastic Syndrome, Refractory Acute Myeloid Leukemia
Interventions
Decitabine, Quizartinib, Venetoclax
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 19, 2026, 11:20 PM EDT